Skip to main content
Top
Literature
3.
go back to reference Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M (2008) Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol 87:253–254 doi:10.1007/s00277-007-0401-8 PubMedCrossRef Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M (2008) Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol 87:253–254 doi:10.​1007/​s00277-007-0401-8 PubMedCrossRef
7.
go back to reference Iwasaki T, Hamano T, Aizawa K et al (1997) Increased serum CA 125 levels in plasma cell dyscrasias. Acta Haematol 98:104–108PubMedCrossRef Iwasaki T, Hamano T, Aizawa K et al (1997) Increased serum CA 125 levels in plasma cell dyscrasias. Acta Haematol 98:104–108PubMedCrossRef
Metadata
Title
Breast and pelvic masses in a myeloma patient
Authors
Y. Y. Hwang
C. S. Chim
G. Chan
F. Loong
T. Yau
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0522-8

Other articles of this Issue 12/2008

Annals of Hematology 12/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine